Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 124 entries
Sorted by: Best Match Show Resources per page
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.

Pharmacology research & perspectives

Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG.
PMID: 26516590
Pharmacol Res Perspect. 2015 Oct;3(5):e00179. doi: 10.1002/prp2.179. Epub 2015 Oct 12.

Evacetrapib is an investigational cholesteryl ester transfer protein inhibitor (CETPi) for reduction of risk of major adverse cardiovascular events in patients with high-risk vascular disease. Understanding evacetrapib disposition, metabolism, and the potential for drug-drug interactions (DDI) may help guide...

Cite
Cannady EA, Wang MD, Friedrich S, et al. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacol Res Perspect. 2015;3(5):e00179doi: 10.1002/prp2.179.
Cannady, E. A., Wang, M. D., Friedrich, S., Rehmel, J. L., Yi, P., Small, D. S., Zhang, W., & Suico, J. G. (2015). Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacology research & perspectives, 3(5), e00179. https://doi.org/10.1002/prp2.179
Cannady, Ellen A, et al. "Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors." Pharmacology research & perspectives vol. 3,5 (2015): e00179. doi: https://doi.org/10.1002/prp2.179
Cannady EA, Wang MD, Friedrich S, Rehmel JL, Yi P, Small DS, Zhang W, Suico JG. Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacol Res Perspect. 2015 Oct;3(5):e00179. doi: 10.1002/prp2.179. Epub 2015 Oct 12. PMID: 26516590; PMCID: PMC4618649.
Copy Download .nbib Format: NLM
Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats.

Nutrition and dietary supplements

Allen PS, Brown AW, Brown MM, Hsu WH, Beitz DC.
PMID: 26752960
Nutr Diet Suppl. 2015;7:77-85. doi: 10.2147/NDS.S88888. Epub 2015 Oct 20.

BACKGROUND: As prescriptions for off-label pharmaceutical use and autonomous administration of over-the-counter nutraceuticals become mainstream, thorough assessments of these compounds are warranted.OBJECTIVE: To determine the effects of gemfibrozil, rosiglitazone, metformin, taurine, and vitamin E on body composition, hepatic lipids,...

Cite
Allen PS, Brown AW, Brown MM, et al. Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats. Nutr Diet Suppl. 2015;7:77-85doi: 10.2147/NDS.S88888.
Allen, P. S., Brown, A. W., Brown, M. M., Hsu, W. H., & Beitz, D. C. (2015). Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats. Nutrition and dietary supplements, 777-85. https://doi.org/10.2147/NDS.S88888
Allen, Portia S, et al. "Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats." Nutrition and dietary supplements vol. 7 (2015): 77-85. doi: https://doi.org/10.2147/NDS.S88888
Allen PS, Brown AW, Brown MM, Hsu WH, Beitz DC. Taurine and vitamin E supplementations have minimal effects on body composition, hepatic lipids, and blood hormone and metabolite concentrations in healthy Sprague Dawley rats. Nutr Diet Suppl. 2015;7:77-85. doi: 10.2147/NDS.S88888. Epub 2015 Oct 20. PMID: 26752960; PMCID: PMC4706234.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
Misleading acute hypercalcemia due to hyperlipidemia: a method-dependent error.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Sachmechi I, Shah G, Rezainadimi L, Blaustein DA, Rosner F.
PMID: 15251784
Endocr Pract. 1997 Sep-Oct;3(5):293-6. doi: 10.4158/EP.3.5.293.

OBJECTIVE: To report a case of artifactual hypercalcemia in a patient with hyperlipidemia.METHODS: We present clinical data and laboratory findings in a 33-year-old woman with generalized fatigue, a recent 5-kg weight loss, and a papular rash on the extremities...

Cite
Sachmechi I, Shah G, Rezainadimi L, et al. Misleading acute hypercalcemia due to hyperlipidemia: a method-dependent error. Endocr Pract. 1997;3(5):293-6doi: 10.4158/EP.3.5.293.
Sachmechi, I., Shah, G., Rezainadimi, L., Blaustein, D. A., & Rosner, F. (1997). Misleading acute hypercalcemia due to hyperlipidemia: a method-dependent error. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 3(5), 293-6. https://doi.org/10.4158/EP.3.5.293
Sachmechi, I, et al. "Misleading acute hypercalcemia due to hyperlipidemia: a method-dependent error." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 3,5 (1997): 293-6. doi: https://doi.org/10.4158/EP.3.5.293
Sachmechi I, Shah G, Rezainadimi L, Blaustein DA, Rosner F. Misleading acute hypercalcemia due to hyperlipidemia: a method-dependent error. Endocr Pract. 1997 Sep-Oct;3(5):293-6. doi: 10.4158/EP.3.5.293. PMID: 15251784.
Copy Download .nbib Format: NLM
Should We Use PPAR Agonists to Reduce Cardiovascular Risk?.

PPAR research

Robinson JG.
PMID: 18288293
PPAR Res. 2008;2008:891425. doi: 10.1155/2008/891425.

Trials of peroxisome proliferator-activated receptor (PPAR) agonists have shown mixed results for cardiovascular prevention. Fibrates are PPAR-alpha agonists that act primarily to improve dyslipidemia. Based on low- and high-density lipoprotein cholesterol (LDL and HDL) effects, gemfibrozil may be of...

Cite
Robinson JG. Should We Use PPAR Agonists to Reduce Cardiovascular Risk?. PPAR Res. 2008;2008:891425doi: 10.1155/2008/891425.
Robinson, J. G. (2008). Should We Use PPAR Agonists to Reduce Cardiovascular Risk?. PPAR research, 2008891425. https://doi.org/10.1155/2008/891425
Robinson, Jennifer G. "Should We Use PPAR Agonists to Reduce Cardiovascular Risk?." PPAR research vol. 2008 (2008): 891425. doi: https://doi.org/10.1155/2008/891425
Robinson JG. Should We Use PPAR Agonists to Reduce Cardiovascular Risk?. PPAR Res. 2008;2008:891425. doi: 10.1155/2008/891425. PMID: 18288293; PMCID: PMC2234387.
Copy Download .nbib Format: NLM
Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature.

Journal of clinical neuromuscular disease

McKelvie PA, Dennett X.
PMID: 19078671
J Clin Neuromuscul Dis. 2002 Jun;3(4):143-8. doi: 10.1097/00131402-200206000-00002.

OBJECTIVE: To examine the clinical profile of patients with myotoxicity due to HMG-CoA reductase inhibitors and the pathological features in the biopsies.DESIGN: All patients receiving HMG-CoA reductase inhibitors who underwent muscle biopsy at the State Neuropathology Service, Melbourne, from...

Cite
McKelvie PA, Dennett X. Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature. J Clin Neuromuscul Dis. 2002;3(4):143-8doi: 10.1097/00131402-200206000-00002.
McKelvie, P. A., & Dennett, X. (2002). Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature. Journal of clinical neuromuscular disease, 3(4), 143-8. https://doi.org/10.1097/00131402-200206000-00002
McKelvie, Penelope A, and Dennett, Xenia. "Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature." Journal of clinical neuromuscular disease vol. 3,4 (2002): 143-8. doi: https://doi.org/10.1097/00131402-200206000-00002
McKelvie PA, Dennett X. Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature. J Clin Neuromuscul Dis. 2002 Jun;3(4):143-8. doi: 10.1097/00131402-200206000-00002. PMID: 19078671.
Copy Download .nbib Format: NLM
Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia).

Journal of clinical lipidology

Blom DJ, Marais AD, Retterstøl K, Stein EA, Ycas J, Gu Z, Miller E.
PMID: 21291775
J Clin Lipidol. 2008 Dec;2(6):418-25. doi: 10.1016/j.jacl.2008.10.002. Epub 2008 Nov 01.

BACKGROUND: Dysbetalipoproteinemia is an uncommon genetic disorder characterized by accumulation of plasma remnant lipoproteins, severe mixed dyslipidemia, elevated apolipoprotein E levels, accelerated atherosclerosis, and premature cardiovascular disease.OBJECTIVE: To evaluate the efficacy and safety of rosuvastatin in patients with dysbetalipoproteinemia.METHODS:...

Cite
Blom DJ, Marais AD, Retterstøl K, et al. Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). J Clin Lipidol. 2008;2(6):418-25doi: 10.1016/j.jacl.2008.10.002.
Blom, D. J., Marais, A. D., Retterstøl, K., Stein, E. A., Ycas, J., Gu, Z., & Miller, E. (2008). Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). Journal of clinical lipidology, 2(6), 418-25. https://doi.org/10.1016/j.jacl.2008.10.002
Blom, Dirk J, et al. "Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia)." Journal of clinical lipidology vol. 2,6 (2008): 418-25. doi: https://doi.org/10.1016/j.jacl.2008.10.002
Blom DJ, Marais AD, Retterstøl K, Stein EA, Ycas J, Gu Z, Miller E. Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). J Clin Lipidol. 2008 Dec;2(6):418-25. doi: 10.1016/j.jacl.2008.10.002. Epub 2008 Nov 01. PMID: 21291775.
Copy Download .nbib Format: NLM
Effect of drugs on high-density lipoprotein.

Journal of clinical lipidology

McKenney JM.
PMID: 21291670
J Clin Lipidol. 2007 Mar;1(1):74-87. doi: 10.1016/j.jacl.2007.01.004. Epub 2007 Feb 15.

The National Cholesterol Education Program Adult Treatment Panel III found evidence for raising high-density lipoprotein cholesterol (HDL-C) to reduce coronary artery disease (CAD) events supports use of HDL-C to help modify low-density lipoprotein cholesterol (LDL-C)-lowering goals, but not to...

Cite
McKenney JM. Effect of drugs on high-density lipoprotein. J Clin Lipidol. 2007;1(1):74-87doi: 10.1016/j.jacl.2007.01.004.
McKenney, J. M. (2007). Effect of drugs on high-density lipoprotein. Journal of clinical lipidology, 1(1), 74-87. https://doi.org/10.1016/j.jacl.2007.01.004
McKenney, James M. "Effect of drugs on high-density lipoprotein." Journal of clinical lipidology vol. 1,1 (2007): 74-87. doi: https://doi.org/10.1016/j.jacl.2007.01.004
McKenney JM. Effect of drugs on high-density lipoprotein. J Clin Lipidol. 2007 Mar;1(1):74-87. doi: 10.1016/j.jacl.2007.01.004. Epub 2007 Feb 15. PMID: 21291670.
Copy Download .nbib Format: NLM
Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine.

Asian Pacific journal of tropical biomedicine

Heidarian E, Rafieian-Kopaei M, Khoshdel A, Bakhshesh M.
PMID: 25183123
Asian Pac J Trop Biomed. 2014 May;4:S429-35. doi: 10.12980/APJTB.4.2014C474.

OBJECTIVE: To evaluate the effects of berberine (BBR) on the liver phosphatidate phosphohydrolase (PAP) and plasma lipids in rats fed on high lipogenic and normal diet.METHODS: Forty rats were randomly divided into 5 groups. Group I (control) received standard...

Cite
Heidarian E, Rafieian-Kopaei M, Khoshdel A, et al. Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine. Asian Pac J Trop Biomed. 2014;4:S429-35doi: 10.12980/APJTB.4.2014C474.
Heidarian, E., Rafieian-Kopaei, M., Khoshdel, A., & Bakhshesh, M. (2014). Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine. Asian Pacific journal of tropical biomedicine, 4S429-35. https://doi.org/10.12980/APJTB.4.2014C474
Heidarian, Esfandiar, et al. "Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine." Asian Pacific journal of tropical biomedicine vol. 4 (2014): S429-35. doi: https://doi.org/10.12980/APJTB.4.2014C474
Heidarian E, Rafieian-Kopaei M, Khoshdel A, Bakhshesh M. Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine. Asian Pac J Trop Biomed. 2014 May;4:S429-35. doi: 10.12980/APJTB.4.2014C474. PMID: 25183123; PMCID: PMC4025298.
Copy Download .nbib Format: NLM
Recurrent Hypertriglyceridemic Pancreatitis (HTGP); and the Use of Insulin Drip as Treatment.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society

Tran T, Lee N.
PMID: 28414683
J La State Med Soc. 2017 Mar-Apr;169(2):55-56. Epub 2017 Apr 15.

INTRODUCTION: Chronic pancreatitis by definition is a recurrent episode of acute pancreatitis and is commonly associated with alcoholism in the US. Another cause of chronic pancreatitis is hypertriglyceridemia (HTGP);, occurring in 1-5 percent of cases. The incidence of HTGP...

Cite
Tran T, Lee N. Recurrent Hypertriglyceridemic Pancreatitis (HTGP); and the Use of Insulin Drip as Treatment. J La State Med Soc. 2017;169(2):55-56
Tran, T., & Lee, N. (2017). Recurrent Hypertriglyceridemic Pancreatitis (HTGP); and the Use of Insulin Drip as Treatment. The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 169(2), 55-56.
Tran, T, and Lee, N. "Recurrent Hypertriglyceridemic Pancreatitis (HTGP); and the Use of Insulin Drip as Treatment." The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society vol. 169,2 (2017): 55-56.
Tran T, Lee N. Recurrent Hypertriglyceridemic Pancreatitis (HTGP); and the Use of Insulin Drip as Treatment. J La State Med Soc. 2017 Mar-Apr;169(2):55-56. Epub 2017 Apr 15. PMID: 28414683.
Copy Download .nbib Format: NLM
Binding Energetics of Charged Amphiphilic Ligands to Thermoresponsive Biodegradable Poly(methoxyethylaminophosphazene) Hydrogels.

Langmuir : the ACS journal of surfaces and colloids

Grinberg VY, Burova TV, Grinberg NV, Papkov VS, Khokhlov AR.
PMID: 31763846
Langmuir. 2019 Dec 24;35(51):16915-16924. doi: 10.1021/acs.langmuir.9b03204. Epub 2019 Dec 10.

Changes in the affinity of the swollen and collapsed forms of a thermoresponsive polymer gel for targeted ligands can be directly estimated using a thermodynamic approach based on high-sensitivity differential scanning calorimetry (HS-DSC). For macromolecular ligands (proteins) bound to...

Cite
Grinberg VY, Burova TV, Grinberg NV, et al. Binding Energetics of Charged Amphiphilic Ligands to Thermoresponsive Biodegradable Poly(methoxyethylaminophosphazene) Hydrogels. Langmuir. 2019;35(51):16915-16924doi: 10.1021/acs.langmuir.9b03204.
Grinberg, V. Y., Burova, T. V., Grinberg, N. V., Papkov, V. S., & Khokhlov, A. R. (2019). Binding Energetics of Charged Amphiphilic Ligands to Thermoresponsive Biodegradable Poly(methoxyethylaminophosphazene) Hydrogels. Langmuir : the ACS journal of surfaces and colloids, 35(51), 16915-16924. https://doi.org/10.1021/acs.langmuir.9b03204
Grinberg, Valerij Y, et al. "Binding Energetics of Charged Amphiphilic Ligands to Thermoresponsive Biodegradable Poly(methoxyethylaminophosphazene) Hydrogels." Langmuir : the ACS journal of surfaces and colloids vol. 35,51 (2019): 16915-16924. doi: https://doi.org/10.1021/acs.langmuir.9b03204
Grinberg VY, Burova TV, Grinberg NV, Papkov VS, Khokhlov AR. Binding Energetics of Charged Amphiphilic Ligands to Thermoresponsive Biodegradable Poly(methoxyethylaminophosphazene) Hydrogels. Langmuir. 2019 Dec 24;35(51):16915-16924. doi: 10.1021/acs.langmuir.9b03204. Epub 2019 Dec 10. PMID: 31763846.
Copy Download .nbib Format: NLM
Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial.

Iranian journal of psychiatry

Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, Sahebolzamani E, Akhondzadeh S.
PMID: 34054983
Iran J Psychiatry. 2021 Jan;16(1):52-59. doi: 10.18502/ijps.v16i1.5379.

No abstract available.

Cite
Zandifar A, Badrfam R, Shamabadi A, et al. Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iran J Psychiatry. 2021;16(1):52-59doi: 10.18502/ijps.v16i1.5379.
Zandifar, A., Badrfam, R., Shamabadi, A., Jalilevand, S., Pourmirbabaei, S., Torkamand, F., Sahebolzamani, E., & Akhondzadeh, S. (2021). Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iranian journal of psychiatry, 16(1), 52-59. https://doi.org/10.18502/ijps.v16i1.5379
Zandifar, Atefeh, et al. "Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial." Iranian journal of psychiatry vol. 16,1 (2021): 52-59. doi: https://doi.org/10.18502/ijps.v16i1.5379
Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, Sahebolzamani E, Akhondzadeh S. Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iran J Psychiatry. 2021 Jan;16(1):52-59. doi: 10.18502/ijps.v16i1.5379. PMID: 34054983; PMCID: PMC8140300.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 124 entries